Hélène SICARD
PhD, Chief Development Officer
A specialist in immuno-oncology R&D, particularly in translational immuno-pharmacology, and in the development of therapeutic antibodies, Hélène Sicard has contributed to several historical programs of Innate Pharma, the French leader in immunotherapy. She established the clinical proof of concept of the lacutamab antibody in Sézary syndrome, a T-cell lymphoma with a very poor prognosis.
Member of the American Society of Clinical Oncology (ASCO), Hélène Sicard holds a PhD in molecular biology from the Paul Sabatier University (Toulouse, France). She conducted her postdoctoral research in the laboratory of Jean Jacques Fournié (Cancer Research Center of Toulouse, CRCT), a world leader in gamma delta T cell biology.